Fabio Cataldi

1.5k total citations · 1 hit paper
72 papers, 1.0k citations indexed

About

Fabio Cataldi is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Fabio Cataldi has authored 72 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Genetics, 34 papers in Epidemiology and 25 papers in Surgery. Recurrent topics in Fabio Cataldi's work include Inflammatory Bowel Disease (48 papers), Microscopic Colitis (32 papers) and Helicobacter pylori-related gastroenterology studies (11 papers). Fabio Cataldi is often cited by papers focused on Inflammatory Bowel Disease (48 papers), Microscopic Colitis (32 papers) and Helicobacter pylori-related gastroenterology studies (11 papers). Fabio Cataldi collaborates with scholars based in United States, Italy and France. Fabio Cataldi's co-authors include Walter Reinisch, William J. Sandborn, Silvio Danese, Mina Hassan‐Zahraee, Séverine Vermeire, Julián Panés, Stefan Schreiber, Geert D’Haens, Dino Tarabar and Maria Kłopocka and has published in prestigious journals such as The Lancet, Gastroenterology and Gut.

In The Last Decade

Fabio Cataldi

71 papers receiving 1000 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

2023 190 citations William J. Sandborn, Séverine Vermeire et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fabio Cataldi United States	15	632	364	303	260	111	72	1.0k
Filip J. Baert Belgium	12	461 0.7×	204 0.6×	340 1.1×	184 0.7×	83 0.7×	35	704
Sonia S. Kupfer United States	13	544 0.9×	367 1.0×	410 1.4×	235 0.9×	156 1.4×	26	1.3k
Liesbeth Lemmens Belgium	11	550 0.9×	160 0.4×	420 1.4×	219 0.8×	155 1.4×	21	895
J Bauditz Germany	16	276 0.4×	192 0.5×	401 1.3×	292 1.1×	160 1.4×	27	1.2k
Colleen McElree United States	10	1.1k 1.7×	545 1.5×	518 1.7×	491 1.9×	172 1.5×	11	1.5k
Pieter Dewint Belgium	16	252 0.4×	293 0.8×	174 0.6×	271 1.0×	115 1.0×	45	1.0k
Diana Luca United States	11	316 0.5×	156 0.4×	229 0.8×	136 0.5×	57 0.5×	26	639
Boyd B. Scott United States	16	648 1.0×	244 0.7×	552 1.8×	214 0.8×	541 4.9×	26	1.5k
P. RUTGEERTS Belgium	14	471 0.7×	136 0.4×	363 1.2×	253 1.0×	71 0.6×	15	759
Maria Carme Masamunt Spain	16	756 1.2×	364 1.0×	409 1.3×	341 1.3×	327 2.9×	39	1.3k

Countries citing papers authored by Fabio Cataldi

Since Specialization

Citations

This map shows the geographic impact of Fabio Cataldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Cataldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Cataldi more than expected).

Fields of papers citing papers by Fabio Cataldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Cataldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Cataldi. The network helps show where Fabio Cataldi may publish in the future.

Co-authorship network of co-authors of Fabio Cataldi

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Cataldi. A scholar is included among the top collaborators of Fabio Cataldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Cataldi. Fabio Cataldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dellon, Evan S., Margaret H. Collins, Albert J. Bredenoord, et al.. (2025). Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial. The Lancet. Gastroenterology & hepatology. 10(7). 622–633. 3 indexed citations

Magro, Fernando, Laurent Peyrin‐Biroulet, Luc Biedermann, et al.. (2025). P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study. Journal of Crohn s and Colitis. 19(Supplement_1). i1251–i1252.

Verstockt, Bram, Rebecca Mosig, Marla C. Dubinsky, Fabio Cataldi, & Silvio Danese. (2024). P077 The Immunometabolic Bimodal Mechanism of NLRX1 Agonist NX-13 in a Pig Model of Ulcerative Colitis. Journal of Crohn s and Colitis. 18(Supplement_1). i344–i345. 1 indexed citations

Verstockt, Bram, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, et al.. (2024). P571 The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to Human. Journal of Crohn s and Colitis. 18(Supplement_1). i1109–i1110. 1 indexed citations

Mosig, Rebecca, et al.. (2024). P086 Identification of a Novel Immunometabolic Target and Agonist for PLXDC2 for Amelioration of DSS Colitis Model in Mice. Journal of Crohn s and Colitis. 18(Supplement_1). i357–i358. 1 indexed citations

Verstockt, Bram, Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2024). P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation. Journal of Crohn s and Colitis. 18(Supplement_1). i396–i397. 1 indexed citations

Danese, Silvio, J F Colombel, Florian Rieder, et al.. (2024). P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases. Journal of Crohn s and Colitis. 18(Supplement_1). i439–i440. 2 indexed citations

D’Haens, Geert, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, et al.. (2023). P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy. Journal of Crohn s and Colitis. 17(Supplement_1). i764–i765. 14 indexed citations

Verstockt, Bram, Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn s and Colitis. 18(5). 762–772. 6 indexed citations

10.

Sandborn, William J., Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 401(10383). 1159–1171. 190 indexed citations breakdown →

11.

D’Haens, Geert, Walter Reinisch, Scott D. Lee, et al.. (2021). Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study. Inflammatory Bowel Diseases. 28(7). 1034–1044. 11 indexed citations

12.

Reinisch, Walter, William J. Sandborn, Silvio Danese, et al.. (2019). DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. Journal of Crohn s and Colitis. 13(Supplement_1). S058–S059. 2 indexed citations

13.

D’Haens, Geert, Walter Reinisch, Dino Tarabar, et al.. (2018). OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study. Journal of Crohn s and Colitis. 12(supplement_1). S017–S018. 5 indexed citations

14.

Sandborn, William J., James D. Lewis, Silvio Danese, et al.. (2018). P533 Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study. Journal of Crohn s and Colitis. 12(supplement_1). S375–S376. 3 indexed citations

15.

Vermeire, Séverine, William J. Sandborn, Silvio Danese, et al.. (2017). Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 390(10090). 135–144. 146 indexed citations

16.

D’Haens, Geert, Dino Tarabar, Édouard Louis, et al.. (2015). OP023. Methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial.. Journal of Crohn s and Colitis. 9(suppl 1). S14–S15. 1 indexed citations

17.

Reinisch, Walter, Julián Panés, Gábor Tóth, et al.. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 64(6). 894–900. 123 indexed citations

18.

Allocca, Mariangela, Gionata Fiorino, Séverine Vermeire, et al.. (2014). Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Review of Clinical Immunology. 10(7). 885–895. 10 indexed citations

19.

Borghi, Battista, Gregory C. Fanelli, D. Celleno, et al.. (1999). Autotransfusion with Predeposit-Haemodilution and Perioperative Blood Salvage: 20 Years of Experience. The International Journal of Artificial Organs. 22(4). 230–234. 5 indexed citations

20.

Borghi, Battista, Elettra Pignotti, Ana Paula Farnezi Bassi, et al.. (1997). Autotransfusion in major orthopaedic surgery: experience with 1785 patients. British Journal of Anaesthesia. 79(5). 662–664. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact